CERUS CORP Exhibit
EX-99.1 2 d687792dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Cerus Announces Preliminary Fourth Quarter and Full Year 2018 Product Revenue 2019 product revenue guidance of $70 million to $73 million,…
To view the full exhibit click here

About CERUS CORPORATION (NASDAQ:CERS)

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.